Journey Medical (DERM) Competitors

$5.18 +0.06 (+1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$5.17 -0.01 (-0.19%)

As of 04:04 PM Eastern

DERM vs. FBIO, PROK, OCGN, STRO, and ALLO

Should you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include Fortress Biotech (FBIO), ProKidney (PROK), Ocugen (OCGN), Sutro Biopharma (STRO), and Allogene Therapeutics (ALLO). These companies are all part of the "medical" sector.

How does Journey Medical compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

: Fortress Biotech has a net margin of 10.77% compared to Journey Medical's net margin of -18.48%. Fortress Biotech's return on equity of -41.20% beat Journey Medical's return on equity.
Company Net Margins Return on Equity Return on Assets
Fortress Biotech 10.77% -41.20% -11.53%
Journey Medical -18.48% -46.40% -13.22%
: 96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 27.9% of Fortress Biotech shares are held by insiders. Comparatively, 15.0% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: Fortress Biotech has higher revenue and earnings than Journey Medical. Fortress Biotech is trading at a lower price-to-earnings ratio than Journey Medical, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fortress Biotech $63.26M 1.29 $6.82M -$0.13 N/A
Journey Medical $61.86M 2.29 -$11.43M -$0.47 N/A
: Fortress Biotech has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.
: Fortress Biotech presently has a consensus target price of $17.00, suggesting a potential upside of 591.06%. Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 150.97%. Given Fortress Biotech's higher probable upside, research analysts clearly believe Fortress Biotech is more favorable than Journey Medical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortress Biotech
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Journey Medical
1 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
: In the previous week, Journey Medical had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Journey Medical and 1 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 equaled Journey Medical'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fortress Biotech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Journey Medical
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	10.77%	-41.20%	-11.53%
Journey Medical	-18.48%	-46.40%	-13.22%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.29	$6.82M	-$0.13	N/A
Journey Medical	$61.86M	2.29	-$11.43M	-$0.47	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Journey Medical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fortress Biotech beats Journey Medical on 10 of the 15 factors compared between the two stocks.

How does Journey Medical compare to ProKidney?

ProKidney (NASDAQ:PROK) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

: Journey Medical has a net margin of -18.48% compared to ProKidney's net margin of -7,725.20%. ProKidney's return on equity of 0.00% beat Journey Medical's return on equity.
Company Net Margins Return on Equity Return on Assets
ProKidney -7,725.20% N/A -18.83%
Journey Medical -18.48% -46.40% -13.22%
: 51.6% of ProKidney shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 39.8% of ProKidney shares are held by company insiders. Comparatively, 15.0% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Journey Medical has higher revenue and earnings than ProKidney. Journey Medical is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ProKidney $890K 651.33 -$68.99M -$0.52 N/A
Journey Medical $61.86M 2.29 -$11.43M -$0.47 N/A
: ProKidney has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.
: ProKidney currently has a consensus target price of $7.40, suggesting a potential upside of 285.42%. Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 150.97%. Given ProKidney's stronger consensus rating and higher possible upside, analysts clearly believe ProKidney is more favorable than Journey Medical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProKidney
2 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.50
Journey Medical
1 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
: In the previous week, Journey Medical had 1 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for Journey Medical and 2 mentions for ProKidney. ProKidney's average media sentiment score of 0.00 equaled Journey Medical'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ProKidney
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Journey Medical
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-7,725.20%	N/A	-18.83%
Journey Medical	-18.48%	-46.40%	-13.22%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	651.33	-$68.99M	-$0.52	N/A
Journey Medical	$61.86M	2.29	-$11.43M	-$0.47	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Journey Medical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ProKidney beats Journey Medical on 10 of the 16 factors compared between the two stocks.

How does Journey Medical compare to Ocugen?

Journey Medical (NASDAQ:DERM) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

: In the previous week, Ocugen had 15 more articles in the media than Journey Medical. MarketBeat recorded 18 mentions for Ocugen and 3 mentions for Journey Medical. Ocugen's average media sentiment score of 0.33 beat Journey Medical's score of 0.00 indicating that Ocugen is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Journey Medical
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ocugen
3 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral
: Journey Medical currently has a consensus target price of $13.00, suggesting a potential upside of 150.97%. Ocugen has a consensus target price of $9.75, suggesting a potential upside of 554.36%. Given Ocugen's stronger consensus rating and higher probable upside, analysts plainly believe Ocugen is more favorable than Journey Medical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Journey Medical
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
Ocugen
1 Sell rating(s)

0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
: Journey Medical has a net margin of -18.48% compared to Ocugen's net margin of -1,192.18%. Journey Medical's return on equity of -46.40% beat Ocugen's return on equity.
Company Net Margins Return on Equity Return on Assets
Journey Medical -18.48% -46.40% -13.22%
Ocugen -1,192.18% -2,626.38% -123.83%
: 7.3% of Journey Medical shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 15.0% of Journey Medical shares are held by company insiders. Comparatively, 4.3% of Ocugen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Journey Medical has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500.
: Journey Medical has higher revenue and earnings than Ocugen. Journey Medical is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Journey Medical $61.86M 2.29 -$11.43M -$0.47 N/A
Ocugen $4.41M 114.30 -$67.85M -$0.23 N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocugen	3 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-18.48%	-46.40%	-13.22%
Ocugen	-1,192.18%	-2,626.38%	-123.83%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.29	-$11.43M	-$0.47	N/A
Ocugen	$4.41M	114.30	-$67.85M	-$0.23	N/A

Summary

Ocugen beats Journey Medical on 10 of the 16 factors compared between the two stocks.

How does Journey Medical compare to Sutro Biopharma?

Journey Medical (NASDAQ:DERM) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

: In the previous week, Sutro Biopharma had 22 more articles in the media than Journey Medical. MarketBeat recorded 25 mentions for Sutro Biopharma and 3 mentions for Journey Medical. Sutro Biopharma's average media sentiment score of 0.85 beat Journey Medical's score of 0.00 indicating that Sutro Biopharma is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Journey Medical
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Sutro Biopharma
3 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
: Journey Medical currently has a consensus target price of $13.00, suggesting a potential upside of 150.97%. Sutro Biopharma has a consensus target price of $40.78, suggesting a potential upside of 9.27%. Given Journey Medical's higher probable upside, equities research analysts plainly believe Journey Medical is more favorable than Sutro Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Journey Medical
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
Sutro Biopharma
2 Sell rating(s)

1 Hold rating(s)

7 Buy rating(s)

3 Strong Buy rating(s)
2.85
: Journey Medical has a net margin of -18.48% compared to Sutro Biopharma's net margin of -186.45%. Sutro Biopharma's return on equity of 0.00% beat Journey Medical's return on equity.
Company Net Margins Return on Equity Return on Assets
Journey Medical -18.48% -46.40% -13.22%
Sutro Biopharma -186.45% N/A -79.02%
: 7.3% of Journey Medical shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 15.0% of Journey Medical shares are held by company insiders. Comparatively, 3.6% of Sutro Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Journey Medical has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.
: Journey Medical has higher earnings, but lower revenue than Sutro Biopharma. Journey Medical is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Journey Medical $61.86M 2.29 -$11.43M -$0.47 N/A
Sutro Biopharma $102.48M 6.03 -$191.09M -$26.10 N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sutro Biopharma	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sutro Biopharma	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-18.48%	-46.40%	-13.22%
Sutro Biopharma	-186.45%	N/A	-79.02%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.29	-$11.43M	-$0.47	N/A
Sutro Biopharma	$102.48M	6.03	-$191.09M	-$26.10	N/A

Summary

Sutro Biopharma beats Journey Medical on 11 of the 17 factors compared between the two stocks.

How does Journey Medical compare to Allogene Therapeutics?

Journey Medical (NASDAQ:DERM) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

: In the previous week, Journey Medical and Journey Medical both had 3 articles in the media. Allogene Therapeutics' average media sentiment score of 0.27 beat Journey Medical's score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Journey Medical
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Allogene Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Allogene Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -18.48%. Journey Medical's return on equity of -46.40% beat Allogene Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Journey Medical -18.48% -46.40% -13.22%
Allogene Therapeutics N/A -57.07% -41.63%
: Journey Medical currently has a consensus target price of $13.00, indicating a potential upside of 150.97%. Allogene Therapeutics has a consensus target price of $8.44, indicating a potential upside of 288.87%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Journey Medical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Journey Medical
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
Allogene Therapeutics
1 Sell rating(s)

3 Hold rating(s)

10 Buy rating(s)

1 Strong Buy rating(s)
2.73
: Journey Medical has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.
: 7.3% of Journey Medical shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 15.0% of Journey Medical shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Journey Medical has higher revenue and earnings than Allogene Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Journey Medical $61.86M 2.29 -$11.43M -$0.47 N/A
Allogene Therapeutics N/A N/A -$190.89M -$0.87 N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-18.48%	-46.40%	-13.22%
Allogene Therapeutics	N/A	-57.07%	-41.63%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.29	-$11.43M	-$0.47	N/A
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.87	N/A

Summary

Allogene Therapeutics beats Journey Medical on 8 of the 15 factors compared between the two stocks.

Get Journey Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DERM vs. The Competition

Export

Metric	Journey Medical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$141.58M	$3.10B	$6.25B	$11.87B
Dividend Yield	N/A	1.91%	2.73%	5.21%
P/E Ratio	-11.02	18.37	29.03	28.47
Price / Sales	2.29	281.03	476.10	60.92
Price / Cash	N/A	50.43	27.62	36.52
Price / Book	5.40	4.33	9.67	6.67
Net Income	-$11.43M	$72.19M	$3.55B	$332.53M
7 Day Performance	-1.52%	2.02%	1.75%	2.03%
1 Month Performance	4.65%	6.41%	5.66%	9.23%
1 Year Performance	-24.60%	37.69%	34.42%	39.62%

Journey Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DERM Journey Medical	1.8275 of 5 stars	$5.18 +1.2%	$13.00 +151.0%	N/A	$141.58M	$61.86M	N/A	90
FBIO Fortress Biotech	2.3601 of 5 stars	$2.24 -1.3%	$17.00 +658.9%	N/A	$73.10M	$63.26M	N/A	170	News Coverage
PROK ProKidney	1.2159 of 5 stars	$1.83 -1.6%	$7.40 +304.4%	N/A	$561.56M	$890K	N/A	3	News Coverage Positive News Upcoming Earnings
OCGN Ocugen	1.5702 of 5 stars	$1.66 -2.4%	$9.75 +487.3%	N/A	$557.42M	$4.41M	N/A	80	Trending News Earnings Report Gap Down
STRO Sutro Biopharma	2.5623 of 5 stars	$34.69 +3.3%	$39.63 +14.2%	N/A	$556.52M	$102.48M	N/A	240	Trending News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DERM) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Journey Medical (DERM) Competitors

DERM vs. FBIO, PROK, OCGN, STRO, and ALLO

How does Journey Medical compare to Fortress Biotech?

Summary

How does Journey Medical compare to ProKidney?

Summary

How does Journey Medical compare to Ocugen?

Summary

How does Journey Medical compare to Sutro Biopharma?

Summary

How does Journey Medical compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM vs. The Competition

Journey Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Journey Medical (DERM) Competitors

DERM vs. FBIO, PROK, OCGN, STRO, and ALLO

How does Journey Medical compare to Fortress Biotech?

Summary

How does Journey Medical compare to ProKidney?

Summary

How does Journey Medical compare to Ocugen?

Summary

How does Journey Medical compare to Sutro Biopharma?

Summary

How does Journey Medical compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM vs. The Competition

Journey Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools